Compositions and methods for inhibition of lineage specific antigens

Patent metadata

Field	Value
Publication number	US-10912799-B2
Application number	US-202016877932-A
Country	US
Kind code	B2
Filing date	May 19, 2020
Priority date	Oct 16, 2015
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.

First claim

What is claimed is:

1. A method of treating a hematopoietic malignancy in a subject in need thereof, the method comprising
(i) administering to the subject an effective amount of a population of genetically engineered human hematopoietic cells, wherein the hematopoietic cells are engineered such that they are deficient in a lineage-specific cell-surface antigen which is expressed by their naturally-occurring hematopoietic cell counterpart.

2. The method of claim 1 , wherein the lineage-specific cell-surface antigen is an antigen that is naturally associated with human leukocytes, a subpopulation of human leukocytes, human myeloid cells, or human plasma cells.

3. The method of claim 1 , wherein the lineage-specific cell-surface antigen is a cluster of differentiation (CD) antigen.

4. The method of claim 3 , wherein the CD antigen is selected from the group consisting of CD19, CD13, CD20, CD22, CD38, CD123, CD33, CD45, CD70, CD312, CD191, CD85D, CD117, CD96, and CD269.

5. The method of claim 4 , wherein the CD antigen is CD33 or CD19.

6. The method of claim 1 , wherein the population of genetically engineered human hematopoietic cells comprises human hematopoietic cells selected from the group consisting of a hematopoietic stem cell, a progenitor cell, a myeloid progenitor cell, a lymphoid progenitor cell, a myeloid cell, a lymphoid cell, and any combination(s) thereof.

7. The method of claim 1 , wherein the population of genetically engineered human hematopoietic cells comprises hematopoietic stem cells.

8. The method of claim 1 , wherein the human hematopoietic cell is obtained from bone marrow, blood, umbilical cord, or peripheral blood mononuclear cells (PBMCs) of a human subject.

9. The method of claim 1 , wherein an endogenous gene encoding the lineage-specific cell-surface antigen is engineered using genome editing.

10. The method of claim 9 , wherein the whole or a portion of the endogenous gene encoding the lineage-specific cell-surface antigen is deleted.

11. The method of claim 9 , wherein the level of the lineage-specific cell-surface antigen is reduced as compared with the level of the lineage-specific cell-surface antigen expressed by its naturally-occurring hematopoietic cell counterpart.

12. The method of claim 9 , wherein the genome editing is a CRISPR system.

13. The method of claim 12 , wherein the CRISPR system comprises a guide nucleic acid that hybridizes to a coding or non-coding sequence of the endogenous gene encoding the lineage-specific cell-surface antigen.

14. The method of claim 12 , wherein the CRISPR system cleaves or produces an insertion, deletion and/or substitution of one or more nucleotides in a coding region or a non-coding region of an endogenous gene encoding the lineage-specific cell-surface antigen.

15. The method of claim 14 , wherein the lineage-specific cell-surface antigen is CD33 or CD19.

16. The method of claim 1 , further comprising (ii) administering to the subject an effective amount of an agent that targets the lineage-specific cell-surface antigen that is deficient in the hematopoietic cells, wherein the agent comprises an antigen-binding fragment that binds said lineage-specific cell-surface antigen.

17. The method of claim 16 , wherein the agent is an antibody or antibody fragment selected from the group consisting of a monoclonal antibody, fully human antibody, humanized antibody, chimeric antibody, single-chain antibody, bi-specific antibody, and a F(ab′)2 fragment.

18. The method of claim 16 , wherein the agent is an immune cell expressing a chimeric receptor that comprises said antigen-binding fragment.

19. The method of claim 18 , wherein the immune cell expressing a chimeric receptor is a T cell and wherein the antigen-binding fragment binds CD33 or CD19.

20. The method of claim 16 , wherein the hematopoietic malignancy is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, and multiple myeloma.

Assignees

• Univ Columbia

Inventors

• Mukherjee Siddhartha
• Borot Florence
• Ali Abdullah Mahmood

Classifications

• A61K40/4252

  Phosphatases · CPC title

• A61K40/421

  Immunoglobulin superfamily · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title